Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lamb Weston Holdings Inc (LW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Lamb Weston Holdings IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Lamb Weston Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lamb Weston Holdings Inc trades at $52.79 (market cap $7.23B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.6× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

LWVRTX
Market Cap
$7.23B$134.25B
Sector
Consumer StaplesHealth
52-Week High
$66.57$529.65
52-Week Low
$38.48$376.62
Enterprise Value
$11.10B$128.37B
Dividend Yield
2.89%

Returns comparison

Trailing returns across standard periods

About Lamb Weston Holdings Inc

Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.

Read more on LW

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX